Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SAN DIEGO, May 11, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced regulatory approvals in select international markets.
Obalon has received notification that it has obtained the necessary regulatory approvals in select Middle East markets to commercialize the Obalon six-month balloon and the associated inflation dispenser. Obalon intends to fulfill an initial order to its Middle East distributor, Bader Sultan, during the second quarter of 2017.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 [email protected] Media: Megan Driscoll EvolveMKD Office Phone: +1 646 517 4220 [email protected]
